Cytoreductive therapy is safe and feasible for newly-diagnosed AML скачать в хорошем качестве

Cytoreductive therapy is safe and feasible for newly-diagnosed AML

Kunhwa Kim, MD, MPH, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, summarizes the results of a post-hoc analysis investigating whether cytoreductive therapy with hydroxyurea or cytarabine can be used as a suitable alternative to immediate induction therapy for urgent disease control in patients with newly-diagnosed acute myeloid leukemia (AML). The study reviewed 276 patients, 35% of whom received cytoreductive therapy prior to starting definitive therapy. No significant difference was found between the complete response (CR) rate, overall survival (OS) or progression-free survival (PFS) of patients who received cytoreduction therapy compared to those who did not. Pretreatment with cytoreductive therapy was found to be safe and feasible in newly-diagnosed AML. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.